COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

Search

Novo Nordisk A-S (Class B)

Cerrado

490.95 3.11

Resumen

Variación precio

24h

Actual

Mínimo

486.95

Máximo

492.1

Métricas clave

By Trading Economics

Ingresos

804M

29B

Ventas

-7.6B

78B

P/B

Media del Sector

20.239

51.198

BPA

6.53

Rentabilidad por dividendo

3.33

Margen de beneficios

37.182

Empleados

77,406

EBITDA

4.1B

39B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+9.53% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.33%

2.40%

Próximas Ganancias

6 ago 2025

Fecha Próximo Dividendo

18 ago 2025

Próxima Fecha de Ex Dividendo

14 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-8B

2T

Apertura anterior

487.84

Cierre anterior

490.95

Novo Nordisk A-S (Class B) Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

16 may 2025, 11:36 UTC

Principales Noticias

Novo Nordisk CEO to Step Down Amid Market Challenges

12 may 2025, 09:36 UTC

Principales Movimientos del Mercado

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7 may 2025, 11:29 UTC

Principales Noticias
Ganancias
Principales Movimientos del Mercado

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

7 may 2025, 07:05 UTC

Ganancias

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales -- Update

7 may 2025, 06:19 UTC

Ganancias

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales

3 jun 2025, 15:03 UTC

Adquisiciones, fusiones, absorciones

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

29 may 2025, 01:00 UTC

Principales Noticias

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

20 may 2025, 14:08 UTC

Ganancias

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

20 may 2025, 07:43 UTC

Charlas de Mercado

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

16 may 2025, 18:35 UTC

Principales Noticias

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 may 2025, 17:34 UTC

Principales Noticias

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

16 may 2025, 13:42 UTC

Acciones populares

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16 may 2025, 13:27 UTC

Charlas de Mercado

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

16 may 2025, 13:15 UTC

Principales Noticias

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

16 may 2025, 12:17 UTC

Ganancias

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

12 may 2025, 22:14 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 may 2025, 18:45 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 may 2025, 12:07 UTC

Charlas de Mercado

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 may 2025, 07:20 UTC

Charlas de Mercado

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7 may 2025, 15:13 UTC

Ganancias

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7 may 2025, 13:56 UTC

Ganancias

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 may 2025, 13:45 UTC

Ganancias

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7 may 2025, 11:25 UTC

Ganancias

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7 may 2025, 11:18 UTC

Ganancias

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 may 2025, 09:55 UTC

Ganancias

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Disney, and More -- Barrons.com

7 may 2025, 09:36 UTC

Ganancias

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Tesla, and More -- Barrons.com

7 may 2025, 09:04 UTC

Ganancias
Acciones populares

Stocks to Watch Wednesday: Disney, Uber, Super Micro -- WSJ

7 may 2025, 08:10 UTC

Charlas de Mercado

Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

7 may 2025, 08:08 UTC

Charlas de Mercado

Novo Nordisk's Downgraded Guidance Assumes Large Wegovy Uplift in 2H -- Market Talk

7 may 2025, 07:11 UTC

Charlas de Mercado
Ganancias

Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

Comparación entre iguales

Cambio de precio

Novo Nordisk A-S (Class B) previsión

Precio Objetivo

By TipRanks

9.53% repunte

Estimación a 12 Meses

Media 1,162.73 DKK  9.53%

Máximo 1,550 DKK

Mínimo 720 DKK

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novo Nordisk A-S (Class B) Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

7

Comprar

2

Mantener

2

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.